Table 4. Treatment-related adverse events during the continuation period.

	Nivolumab followed by ipilimumab (n=32)			Ipilimumab followed by nivolumab (n=32)
	Grade 1–2	Grade 3	Grade 4	Grade 1–2	Grade 3	Grade 4
Increased lipase	5 (16%)	5 (16%)	2 (6%)	6 (19%)	4 (13%)	2 (6%)
Increased amylase	8 (25%)	1 (3%)	1 (3%)	4 (13%)	1 (3%)	0
Increased ALT	7 (22%)	0	0	6 (19%)	0	0
Increased AST	6 (19%)	0	0	3 (9%)	0	0
Increased bloodthyroid-stimulatinghormone	2 (6%)	0	0	4 (13%)	0	0
Pruritus	8 (25%)	0	0	10 (31%)	0	0
Vitiligo	8 (25%)	0	0	10 (31%)	0	0
Rash	5 (16%)	0	0	7 (22%)	0	0
Rash (maculopapular)	6 (19%)	0	0	3 (9%)	1 (3%)	0
Diarrhoea	9 (28%)	1 (3%)	0	2 (6%)	1 (3%)	0
Nausea	7 (22%)	0	0	3 (9%)	0	0
Vomiting	4 (13%)	0	0	4 (13%)	0	0
Abdominal pain	2 (6%)	0	0	3 (9%)	2 (6%)	0
Colitis	1 (3%)	0	0	0	1 (3%)	0
Acute pancreatitis	0	0	0	0	2 (6%)	0
Hypothyroidism	7 (22%)	0	0	8 (25%)	0	0
Adrenal insufficiency	1 (3%)	1 (3%)	1 (3%)	2 (6%)	0	0
Fatigue	13 (41%)	2 (6%)	0	4 (13%)	0	0
Arthralgia	5 (16%)	1 (3%)	0	4 (13%)	0	0
Back pain	0	1 (3%)	0	1 (3%)	0	0
Muscle spasms	1 (3%)	1 (3%)	0	0	0	0
Hyperglycaemia	4 (13%)	1 (3%)	0	0	2 (6%)	0
Cough	4 (13%)	0	0	1 (3%)	0	0
Pneumonitis	3 (9%)	1 (3%)	0	1 (3%)	0	0
Headache	4 (13%)	0	0	2 (6%)	0	0
Encephalitis	0	0	1 (3%)	0	0	0
Hypertension	0	1 (3%)	0	0	0	0
Cardiac failure	0	1 (3%)	0	0	0	0
Deafness	0	1 (3%)	0	0	0	0
Hearing impaired	0	1 (3%)	0	0	0	0

Data are n (%). ALT=alanine aminotransferase. AST=aspartate aminotransferase. No treatment-related deaths were recorded.